Arlington Capital Partners a Washington, D.C.–based private investment firm with a focus on government-regulated industries, announced today that its portfolio company TEAM Technologies (“TEAM Tech”) has acquired TAG3 Engineering, LLC (“TAG3”).
TEAM Tech is a leading provider of end-to-end outsourced manufacturing for mission-critical medical devices, serving global healthcare OEMs. The acquisition of TAG3 significantly enhances TEAM Tech’s design and development expertise, particularly in the rapidly expanding markets of interventional cardiology and neurovascular devices. Notably, TAG3 is the third acquisition completed by TEAM Tech within the first year of Arlington’s ownership, underscoring the firm’s commitment to accelerating TEAM Tech’s growth trajectory.
Expanding Front-End Design Capabilities
TAG3 Engineering has built a reputation as a premier designer, developer, and manufacturer of complex interventional medical devices. The company’s specialty lies in front-end design for next-generation devices, an area of increasing importance as medical technology companies seek faster and more efficient ways to bring products from concept to commercialization.
The TAG3 acquisition builds on TEAM Tech’s earlier acquisition of Duke Empirical (“Duke”), a recognized leader in the design and manufacturing of innovative catheters and minimally invasive delivery systems. Together, Duke and TAG3 strengthen TEAM Tech’s ability to deliver a complete, turnkey solution—from initial design and prototyping through clinical trials and commercial-scale production.
This end-to-end model allows TEAM Tech to meet the evolving needs of MedTech OEMs by accelerating development timelines, reducing costs, and simplifying the supply chain for mission-critical medical devices.
Strategic Alignment with Growth Markets
TEAM Tech’s strategy under Arlington’s ownership has centered on expanding its capabilities in minimally invasive surgical devices, one of the fastest-growing segments in the healthcare industry. Devices used in interventional cardiology, neurovascular surgery, and related therapeutic areas are in high demand as physicians increasingly turn to less invasive techniques to improve patient outcomes.
“The acquisition of TAG3 further enhances TEAM Tech’s fast-growing minimally invasive surgical franchise,” said Matt Altman, Managing Partner at Arlington Capital Partners. “We are excited to partner with the exceptional TAG3 team to further support our healthcare customers from innovative design all the way through commercial production.”
This strategy reflects Arlington’s focus on building integrated platforms that can support healthcare companies at every stage of the product lifecycle. By combining strong design expertise with advanced manufacturing capabilities, TEAM Tech is becoming an indispensable partner to OEMs navigating complex regulatory environments and high-performance device requirements.
Leadership Perspectives
Marshall White, President and CEO of TEAM Tech, highlighted how TAG3’s design capabilities complement TEAM Tech’s existing strengths:
“TAG3 is the perfect complement to our growing platform. Its front-end design expertise will accelerate the speed to market of mission-critical devices by seamlessly combining with the large-scale commercialization capabilities of TEAM Tech. With these added capabilities, we are even better positioned to provide exceptional value to healthcare OEMs, and we are thrilled to welcome TAG3 to TEAM Tech.”
Gordon Auduong, Managing Director at Arlington Capital Partners, emphasized the technical depth TAG3 brings:
“TAG3 adds world-class design and development capabilities for complex Class II and Class III medical devices to TEAM Tech’s portfolio, along with expertise in advanced technologies such as electrospinning, hydrophilic coatings, and proprietary polymer blending. Together with Duke, TAG3 positions TEAM Tech as a true end-to-end partner in the most attractive medical device markets, accelerating speed to market for innovators building life-saving devices.”
Arlington’s Broader Healthcare Investment Strategy
Arlington Capital Partners has an extensive track record of building companies in healthcare and other highly regulated sectors. The firm focuses on partnering with management teams to create businesses that:
- Deliver innovative therapies and technologies that save lives
- Improve the efficiency of healthcare delivery
- Reduce costs for patients and providers
Recent healthcare investments by Arlington include AVS Bio, Afton Scientific, Everest Clinical Research, Grand River Aseptic Manufacturing, Millstone Medical Outsourcing, and Riverpoint Medical. This consistent investment strategy highlights Arlington’s commitment to long-term value creation in industries where innovation and regulatory compliance are paramount.
Advisors on the Transaction
As part of the TAG3 transaction:
- Solomon Partners served as financial advisor to TEAM Tech and Arlington.
- Bonifacio Consulting Services (BCS) acted as operational advisor, supporting integration planning and execution.
Looking Ahead
With the addition of TAG3, TEAM Tech is positioned as a comprehensive partner for medical device innovators, offering services that span the entire product lifecycle—from early-stage concept development to high-volume manufacturing. This capability is increasingly valuable in a MedTech environment where speed to market, reliability, and compliance can determine the success of new devices.
By continuing to expand its design, development, and manufacturing expertise through strategic acquisitions, TEAM Tech is not only scaling its own operations but also helping healthcare innovators deliver advanced, life-saving technologies to patients worldwide.
As Arlington Capital Partners and TEAM Tech look ahead, the integration of TAG3 represents another step toward building a leading global platform for mission-critical medical devices, one that can serve as a vital partner for the next generation of MedTech breakthroughs.
About Arlington Capital Partners
Arlington Capital Partners is a Washington, D.C.-area private investment firm specializing in government-regulated industries. The firm partners with founders and management teams to build strategically important businesses in the healthcare, government services and technology, and aerospace and defense sectors. Since its inception in 1999, Arlington has invested in over 180 companies and has raised ~$14 billion in committed capital. For more information, visit Arlington’s website at www.arlingtoncap.com and follow Arlington on LinkedIn.
About TEAM Technologies
Headquartered in Knoxville, TN, with facilities throughout the United States and international facilities in Mexico and Singapore, TEAM Technologies is a specialized end-to-end outsourced manufacturer of mission-critical, single-use medical devices. The company has an extensive array of advanced and vertically integrated manufacturing solutions servicing top medical device and pharmaceutical OEMs. With its deep industry experience and reputation for the highest quality standards, TEAM Technologies leverages seamless, turnkey processes and innovation to dramatically simplify and improve its customers’ supply chains. For more information, visit teamtech.com.
About TAG3
TAG3 Engineering is a full-service MedTech design, development, and manufacturing partner, dedicated to driving innovation in the development of medical devices. With a focus on excellence and collaboration, TAG3 Engineering partners with medical device companies to accelerate design and development. TAG3 can tackle the full spectrum of needs that arise in all phases of the medical device lifecycle—from concept to commercialization. TAG3Engineering.com.
